Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 46

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 46
---
 the Company’s performance measures with compensation that is actually paid (as computed in accordance with SEC rules) for a particular year. In accordance with SEC rules, we are providing the following descriptions of the relationships between information presented in the Pay versus Performance table. Compensation Actually Paid, Cumulative TSR, and Peer Group TSR

32

TABLE OF CONTENTS

Compensation Actually Paid and Net Income (Loss) Financial Performance Measures As described in greater detail in the Compensation Discussion and Analysis section, the Company’s executive compensation program reflects a variable pay-for-performance philosophy. The metrics that the Company uses for our short-term incentive awards are selected based on an objective of incentivizing our NEOs to increase the value of our enterprise for our shareholders. The Company does not currently use any financial performance measures to link executive compensation actually paid to our performance. However, the most important performance measures used by the Company to link executive compensation actually paid to the Company’s NEOs, for the most recently completed fiscal year, to the Company’s performance are as follows:

| • | Delivering the SLK global programs in Hidradenitis Suppurativa and Psoriatic Arthritis including study initiation and enrolment as per plans; |

| • | Securing financial stability by raising capital and managing cash burn; and |

| • | Building the Company and its profile with key stakeholders including execution against hiring plans. |

33

TABLE OF CONTENTS

CERTAIN INFORMATION ABOUT OUR ORDINARY SHARES Security Ownership of Certain Beneficial Owners and Management The following table sets forth information known to us regarding the beneficial ownership of our voting ordinary shares as of March 15, 2025, by:

| • | each shareholder or group of shareholders known by us to be the beneficial owner of more than five percent (5%) of the outstanding shares of each class of our voting ordinary shares; |

| • | each of our directors and nominees; |

| • | each of our named executive officers; and |

| • | all of our current directors and executive officers as a group. |

Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including any shares that the individual has the right to acquire within 60 days after the date of this table. Unless otherwise indicated, to our knowledge and subject to community property rules, we believe that all persons named in the table below have sole voting and sole investment power with respect to the voting securities